Cumberland Pharmaceuticals Files 8-K

Ticker: CPIX · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1087294

Sentiment: neutral

Topics: financial-reporting, sec-filing

Related Tickers: CPRX

TL;DR

CPRX filed an 8-K for financial updates, check for details.

AI Summary

Cumberland Pharmaceuticals Inc. filed an 8-K on March 4, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the period ending March 4, 2025. No specific financial figures or significant events were detailed in the provided excerpt.

Why It Matters

This filing indicates Cumberland Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification without specific negative or positive financial disclosures, making the immediate risk level low.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K filing?

The provided excerpt states the filing is for 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but does not detail specific financial figures.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is March 4, 2025.

What is Cumberland Pharmaceuticals Inc.'s Standard Industrial Classification code?

The SIC code for Cumberland Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Where are Cumberland Pharmaceuticals Inc.'s principal executive offices located?

The principal executive offices are located at 2525 West End Avenue, Suite 950, Nashville, Tennessee 37203.

What is the SEC file number for Cumberland Pharmaceuticals Inc.?

The SEC file number for Cumberland Pharmaceuticals Inc. is 001-33637.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding CUMBERLAND PHARMACEUTICALS INC (CPIX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing